Efficacy of aerosolized tobramycin in patients with cystic fibrosis

Article Abstract:

Aerosolized tobramycin may be an effective treatment for Pseudomonas aeruginosa infections in patients with cystic fibrosis. Pseudomonas aeruginosa infections are a major complication of cystic fibrosis. Sixty-six cystic fibrosis patients with documented Pseudomonas aeruginosa infections participated in a crossover study of aerosolized tobramycin. Approximately half inhaled the antibiotic through a nebulizer three times a day for 28 days, then switched to a placebo, or inactive substance. The others started on the placebo, then switched to tobramycin. Both groups experienced an improvement in lung function on tobramycin compared to placebo. In addition, the concentration of the bacterium in sputum samples dropped substantially during tobramycin treatment. Few patients experienced kidney damage or hearing loss. These are both side effects of aminoglycosides, the group of antibiotics to which tobramycin belongs.

Dosage and administration, Aerosol therapy

---

Management of pulmonary disease in patients with cystic fibrosis

Article Abstract:

Improvements in the treatment for cystic fibrosis have significantly prolonged lifespans. Cystic fibrosis is caused by a defect in the gene for a protein that transports chloride. The defect in chloride transport causes an overproduction of secretions that block the pancreas and cause lung infections. The primary treatment is replacing pancreatic enzymes and clearing abnormal lung secretions. In addition, many CF patients have to take antibiotics to prevent lung infections. These can often be administered using an inhaler. The defective gene has been sequenced, leading to the possibility of gene therapy for this disease.

Care and treatment

---

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis

Article Abstract:

Inhaled tobramycin may improve lung function in cystic fibrosis patients. Researchers randomly assigned 520 cystic fibrosis patients to inhale tobramycin or a placebo twice a day for four weeks. The patients alternated between inhalations of placebo or tobramycin for 24 weeks total. Tobramycin improved lung function, reduced the rate of infection with Pseudomonas aeruginosa, and led to lower hospitalization rates. The drug caused few side effects. Intermittent treatment may prevent Pseudomonas aeruginosa from becoming resistant to the drug.

Similar abstracts:

• Abstracts: Lack of efficacy of phenytoin in recessive dystrophic epidermolysis bullosa. Nonmelanoma cancers of the skin
• Abstracts: Ethical implications of rejecting patients for clinical trials
• Abstracts: Brief report: trimethoprim-induced hyperkalemia in a patient with AIDS. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system
• Abstracts: A controlled trial of bismuth subsalicylate in infants with acute watery diarrheal disease. Racecadotril in the treatment of acute watery diarrhea in children
• Abstracts: Gustatory and olfactory considerations: examination and treatment in general practice. Hyposalivation, xerostomia and the complete denture: a systematic review

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.